Since recent studies have shown the efficacy and tolerance of sitagliptin as cancer therapeutic, it would be interesting to further investigate its activities as a target for DPP4/CTNNB1/MET signaling pathways in THCA, both in vitro and in vitro in tumor-bearing mice. This evidence concerns the gene CTNNB1 and cancer.